TMCI
TREACE MEDICAL CONCEPTS, INC.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Apr 9 Treace Medical Concepts issued a preliminary Q1 2026 outlook showing…
- May 8 ▼ Treace Medical Concepts reported Q1 2026 revenue of $47.2M (down 10%…
- May 12 to May 14 ▲ 3 days of insider buys: $375.5K by 1 insider, avg $2.44
- May 26 to Jun 1 ▲ 4 days of insider buys: $518.5K by 1 insider, avg $3.13
- Jun 10 to Jun 11 ▲ 2 days of insider buys: $310.2K by 1 insider, avg $4.03
- Jul 13 TREACE MEDICAL CONCEPTS, INC. v. STRYKER CORPORATION et al
- Aug 7 Treace Medical Concepts reported Q2 2026 revenue of $45.4M (down 4%…
- Aug 20 to Aug 24 ▲ 3 days of insider buys: $246.7K by 1 insider, avg $4.41
- Nov 6 ▲ Earnings: TMCI Q3 2026 Earnings: EPS $-0.19 (+26.7% vs est)
- Nov 9 ▲ Stifel upgrades
- Nov 12 TREACE MEDICAL CONCEPTS, INC. v. STRYKER CORPORATION et al
Signal stack
Where each data set points today.
- InsidersBULLISH
1 insider bought $1.5M at an average $3.21. No open-market sales. Price is 38% above their cost.
- InstitutionsBEARISH
Q3 2026: 8 added (0 new), 20 trimmed or exited.
- AnalystsMIXED
1 of 10 rate it Buy or better. Every target is above the price.
- EstimatesFALLING
Current-quarter EPS estimate −$0.080 → −$0.110 over 90 days. 1 up, 0 down in 30 days.
- Short sellersSTEADY
Short interest −6.9% to 1.79M shares. 8.7 days to cover, ≈2.7% of shares.
- TrendUPTREND
1% above its 50-day average. New closing high $5.34 on Nov 12.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| ROYAL BANK OF CANADA | NEAR_EXIT | Not reported |
| MILLENNIUM MANAGEMENT LLC | ADD | $5.5M |
| D. E. Shaw & Co., Inc. | ADD | $3.5M |
| AQR CAPITAL MANAGEMENT LLC | TRIM | $2.3M |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | ADD | $1.5M |
| CITADEL ADVISORS LLC | TRIM | $1.3M |
| MORGAN STANLEY | TRIM | $626.5K |
| Jain Global LLC | TRIM | $617.2K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
10 analystsPrice is below the lowest target. Median implies +46%.Targets as of Nov 18, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 9, 2026 | Stifel UPGRADE | Buy |
| Aug 10, 2026 | Truist Securities MAINTAIN | Hold |
| Jul 16, 2026 | Truist Securities MAINTAIN | Hold |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Scanlan Sean F. Chief Innovation Officer Oct 24, 2026 | TAX W/H | 207 sh |
Elder Scot Michael Chief Legl & Comp Off, CorpSec Sep 30, 2026 | TAX W/H | 25,457 sh |
Treace John T. Chief Executive Officer Aug 24, 2026 | BUY | $47.7K |
Treace John T. Chief Executive Officer Aug 21, 2026 | BUY | $21.7K |
Treace John T. Chief Executive Officer Aug 20, 2026 | BUY | $177.2K |
Scanlan Sean F. Chief Innovation Officer Aug 9, 2026 | TAX W/H | 9,814 sh |
Hair Mark Chief Financial Officer Aug 9, 2026 | TAX W/H | 37,102 sh |
Elder Scot Michael Chief Legl & Comp Off, CorpSec Aug 9, 2026 | TAX W/H | 16,253 sh |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$0.11 | -$0.11–-$0.11 | -22.2% | $67.2M |
| Next Q | -$0.27 | -$0.29–-$0.26 | -10.2% | $50.6M |
| Current FY | -$0.81 | -$0.85–-$0.80 | +4.6% | $208.0M |
| Next FY | -$0.76 | -$0.79–-$0.73 | +1.9% | $220.7M |
Short side
FINRA· Oct 30, 2026SecBot reports
11 filings · 0 bullish · 3 bearish · 2 mixed · 6 neutral- NEUTRAL SC 13GNov 16, 2026
Armistice Capital filed a new Schedule 13G disclosing a 9.79% passive stake in Treace Medical…
Armistice Capital's re-accumulation to a 9.79% stake signals renewed conviction after a prior exit. Monitor for any subsequent 13D conversion or engagement with management, though the filing…
- BEARISH SC 13G/ANov 16, 2026
Armistice Capital filed an amended Schedule 13G disclosing a 1.96% passive stake in Treace Medical…
Monitor for further insider or institutional selling. Armistice Capital's exit below 5% removes a passive holder that previously held a meaningful position, potentially reducing support for the stock.
- NEUTRAL COURT-RULINGNov 12, 2026
The court issued a Markman claim construction ruling in Treace Medical's patent infringement suit…
The claim construction is mixed but slightly favorable to Treace on the core 'bone positioning guide' term. The case continues toward summary judgment or trial on infringement. Monitor for summary…
- NEUTRAL 8-KNov 6, 2026
Treace Medical Concepts reported Q3 2026 revenue of $48.3M, down 4% YoY from $50.2M, but net loss…
Revenue continues to decline YoY but the pace of decline is moderating and the company reached positive Adjusted EBITDA for the first time. Watch for Q4 revenue to see if the improving…
All TMCI filing & press-release reports (11)
- SC 13G reportNov 16, 2026
- SC 13G/A reportNov 16, 2026
- COURT-RULING reportNov 12, 2026
- 8-K reportNov 6, 2026
- PRESS-RELEASE reportSep 17, 2026
- 8-K reportAug 7, 2026
- COURT-RULING reportJul 13, 2026
- PRESS-RELEASE reportMay 8, 2026
- PRESS-RELEASE reportApr 24, 2026
- 8-K reportApr 9, 2026
- DEFA14A reportApr 6, 2026